IN2012DN01328A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01328A
IN2012DN01328A IN1328DEN2012A IN2012DN01328A IN 2012DN01328 A IN2012DN01328 A IN 2012DN01328A IN 1328DEN2012 A IN1328DEN2012 A IN 1328DEN2012A IN 2012DN01328 A IN2012DN01328 A IN 2012DN01328A
Authority
IN
India
Prior art keywords
rsv
protein
treatment
methods
immunospecifically bind
Prior art date
Application number
Inventor
Robert Anthony Williamson
Jehangir Wadia
Gabriel Pascual
Elissa Keogh
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of IN2012DN01328A publication Critical patent/IN2012DN01328A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
IN1328DEN2012 2009-08-13 2010-08-13 IN2012DN01328A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27439509P 2009-08-13 2009-08-13
PCT/US2010/045549 WO2011020079A1 (en) 2009-08-13 2010-08-13 Antibodies against human respiratory syncytial virus (rsv) and methods of use

Publications (1)

Publication Number Publication Date
IN2012DN01328A true IN2012DN01328A (en) 2015-06-05

Family

ID=43014487

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1328DEN2012 IN2012DN01328A (en) 2009-08-13 2010-08-13

Country Status (18)

Country Link
US (2) US8568719B2 (en)
EP (1) EP2464664B1 (en)
JP (1) JP5762408B2 (en)
KR (1) KR101778317B1 (en)
CN (1) CN102656189B (en)
BR (1) BR112012003064B8 (en)
CA (1) CA2770737C (en)
DK (1) DK2464664T3 (en)
EA (1) EA023179B1 (en)
ES (1) ES2553440T3 (en)
IL (1) IL217977A (en)
IN (1) IN2012DN01328A (en)
MX (1) MX2012001882A (en)
NZ (1) NZ597996A (en)
PL (1) PL2464664T3 (en)
SG (1) SG178335A1 (en)
WO (1) WO2011020079A1 (en)
ZA (1) ZA201201007B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01328A (en) 2009-08-13 2015-06-05 Crucell Holland Bv
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
PT2710033T (en) 2011-05-17 2021-03-11 Univ Rockefeller Human immunodeficiency virus neutralizing antibodies and methods of use thereof
WO2013000982A1 (en) * 2011-06-27 2013-01-03 Vivalis Method for screening cells
WO2013006544A1 (en) * 2011-07-06 2013-01-10 Medimmune, Llc Methods for making multimeric polypeptides
AU2012362378B2 (en) * 2011-12-27 2016-06-23 Dcb-Usa Llc Light chain-bridged bispecific antibody
WO2013135655A1 (en) * 2012-03-13 2013-09-19 Universiteit Utrecht Holding B.V. Bi-specific adapters
DK2828293T3 (en) * 2012-03-20 2018-01-08 Humabs Biomed S A ANTIBODIES NEUTRALIZING RSV, MPV AND PVM AND USE THEREOF
EP3838923B1 (en) 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CN103048459B (en) * 2012-12-05 2014-08-20 中国科学院武汉病毒研究所 Immune detection reagent for detecting respiratory syncytial virus
RS62304B1 (en) 2013-03-14 2021-09-30 Macrogenics Inc BISPECIFIC MOLECULES WHICH ARE IMMUNOREACTIVE WITH IMMUNE EFFECTIVE CELLS EXPRESSING AN ACTIVATING RECEPTOR
TWI659968B (en) 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
TR201902513T4 (en) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilized soluble prefusion RSV F polypeptides.
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
DK3012633T3 (en) * 2013-06-21 2018-08-13 Alfresa Pharma Corp Immunochromatography device for detection of RSV
US10047145B2 (en) 2013-07-24 2018-08-14 Humabs Biomed Sa Antibodies that potently neutralize RSV and uses thereof
PL3068417T3 (en) * 2013-11-15 2024-05-13 F.Hoffmann-La Roche Ag Methods for viral inactivation using eco-friendly detergents
CN103911389A (en) * 2014-04-09 2014-07-09 南昌大学 Preparation method of G and F protein for detecting human respiratory syncytial virus antibody
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
SG11201610446XA (en) 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN105319373B (en) * 2014-08-18 2017-01-18 董俊 Rapid human respiratory syncytial virus detection method and kit based on magnetic separating and quantum dot labeling
BR112017006515A8 (en) 2014-09-29 2018-02-27 Univ Duke bispecific molecules, compositions, method for treating or preventing HIV-1 infection in an individual with this need, and vector
KR20170093120A (en) * 2014-10-10 2017-08-14 아블린쓰 엔.브이. Methods of treating rsv infections
US20180185404A1 (en) * 2015-07-02 2018-07-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
ES2839880T3 (en) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv RSV vaccine
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme An antibody that inactivates the human pneumonia virus
CN106496324B (en) 2015-11-30 2020-01-14 天津昊免生物技术有限公司 Fully human antibody for resisting respiratory syncytial virus
CN109232737A (en) * 2016-03-01 2019-01-18 苏州博泰神州生物技术有限公司 A kind of full human monoclonal antibody for RSV attachment G protein surface antigen
CN105753981B (en) * 2016-03-08 2019-10-08 湖北工业大学 The immune chromatography reagent kit of anti-human Respiratory Syncytial Virus(RSV) N protein antibody and the application antibody
EP3439694A1 (en) 2016-04-05 2019-02-13 Janssen Vaccines & Prevention B.V. Vaccine against rsv
PT3439672T (en) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
US11084796B2 (en) * 2016-05-10 2021-08-10 Georgia State University Research Foundation, Inc. Heterocyclic derivatives for the treatment of RSV
KR102421049B1 (en) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. Stabilized pre-fusion RSV F protein
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
EP3528840A1 (en) * 2016-10-21 2019-08-28 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
KR20200053518A (en) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Method for safe induction of immunity to RSV
SG11202104522UA (en) 2018-11-13 2021-05-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
WO2020124846A1 (en) * 2018-12-18 2020-06-25 珠海泰诺麦博生物技术有限公司 Neutralizing antibody against respiratory syncytial virus and use thereof
CL2018003869A1 (en) 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Monoclonal antibodies specific for human parainfluenza virus chimeric protein I (piv), nucleotide sequences; PIV infection diagnostic method and kit
EP3969045A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
WO2020229577A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
US20220308055A1 (en) * 2019-08-27 2022-09-29 University Of Central Florida Research Foundation, Inc. Method and device for pathogen or antibody detection using unmodified signaling substances with or without unlabeled detection reagents
CN111166881B (en) * 2020-01-06 2023-03-24 国药中生生物技术研究院有限公司 Recombinant respiratory syncytial virus multi-epitope chimeric vaccine and preparation method and application thereof
EP4126023A1 (en) 2020-04-02 2023-02-08 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
AU2021302535A1 (en) 2020-06-29 2023-02-09 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
CN116113707A (en) * 2020-08-31 2023-05-12 基因泰克公司 Methods for producing antibodies
FR3114970B1 (en) * 2020-10-08 2023-06-30 Univ Tours COMBINATION OF INHALED ANTIBODIES WITH IMMUNO-MODULATING AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS
US20240059763A1 (en) * 2020-12-18 2024-02-22 Zhuhai Trinomab Pharmaceutical Co., Ltd. Respiratory syncytial virus-specific binding molecule
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN113249333B (en) * 2021-03-16 2023-06-02 贵州省人民医院 A Hybridoma Cell Line RSVN4C3 Secreting Anti-Respiratory Syncytial Virus Monoclonal Antibody
WO2022268120A1 (en) * 2021-06-22 2022-12-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-rsv antibodies and uses thereof
MX2024001867A (en) * 2021-08-10 2024-03-04 Icosavax Inc Virus-like particle vaccine for respiratory syncytial virus.
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof
CN117924472B (en) * 2024-02-04 2025-02-18 北京微星生物科技有限公司 Antibodies against respiratory syncytial virus
CN117964750B (en) * 2024-02-04 2024-10-25 北京微星生物科技有限公司 Monoclonal antibody for resisting respiratory syncytial virus and application thereof

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
SE459008B (en) 1986-09-04 1989-05-29 Bioinvent Int Ab MAKE PRODUCING HUMAN MONOCLONAL ANTIBODIES
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE68921982T4 (en) 1988-06-14 1996-04-25 Cetus Oncology Corp COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
SE461985B (en) 1988-09-13 1990-04-23 Bioinvent Int Ab IN VITRO IMMUNIZATION OF Lymphocyte-containing CELL POPULATIONS AND MATERIAL KIT
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
NL8902087A (en) 1989-08-17 1991-03-18 Stichting Tech Wetenschapp NON-NATURALLY AVOIDING PSEUDORABIES VIRUS AND VACCINES CONTAINING THIS.
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (en) 1990-03-20 1997-10-15 Univ Columbia CHIMERIC ANTIBODIES WITH RECEPTOR-BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
CA2093022C (en) 1990-10-05 2005-02-22 Michael W. Fanger Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
DK0574395T3 (en) 1990-11-09 2002-10-07 Stephen D Gillies Cytokine immunoconjugates
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
JP3242916B2 (en) * 1990-12-14 2001-12-25 セル ジェネシス，インコーポレイティド Chimeric chains for receptor-related signal transduction systems
DE69233750D1 (en) * 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
ES2093778T3 (en) * 1991-04-26 1997-01-01 Surface Active Ltd NEW ANTIBODIES AND METHODS FOR USE.
ES2181673T3 (en) 1991-05-01 2003-03-01 Jackson H M Found Military Med PROCESS OF TREATMENT OF INFECTIOUS RESPIRATORY DISEASES.
DE69231736T2 (en) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad TARGETED DELIVERY OF GENES ENCODING IMMUNOGENIC PROTEINS
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ATE195656T1 (en) 1991-06-05 2000-09-15 Univ Connecticut TARGETED RELEASE OF GENES ENCODING SECRETORY PROTEINS
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ATE239506T1 (en) 1992-03-05 2003-05-15 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2191016T3 (en) 1992-09-16 2003-09-01 Scripps Research Inst HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES FOR THE SYNCTIAL RESPIRATORY VIRUS.
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
DE69330167T2 (en) 1992-10-09 2001-11-15 Advanced Tissue Sciences, Inc. LIVER RESERVE CELLS
JPH08503855A (en) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション Gene therapy for cystic fibrosis
US5359681A (en) * 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
ATE300610T1 (en) 1994-01-31 2005-08-15 Univ Boston LIBRARIES OF POLYCLONAL ANTIBODIES
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) * 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
JPH10503371A (en) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー New compound
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
EP0805628B1 (en) 1995-01-17 2003-05-02 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5840300A (en) 1995-09-11 1998-11-24 Trustees Of The University Of Pennsylvania Methods and compositions comprising single chain recombinant antibodies
WO1997010846A1 (en) * 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
JP2978435B2 (en) * 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
WO1997032572A2 (en) 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5842307A (en) 1996-11-15 1998-12-01 May; Kenzel Self-adjusting, automatic spot weed sprayer
KR100643058B1 (en) 1996-12-03 2006-11-13 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
TR199902553T2 (en) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh New methods and uses for the production of antigen receptors against the human body.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
HUP9900956A2 (en) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Single-chain multiple antigen-binding molecules, their preparation and use
EP1089712B1 (en) 1998-06-24 2003-05-02 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1265928B1 (en) 2000-01-27 2010-07-21 Medimmune, LLC Ultra high affinity rsv neutralizing antibodies
US20050175986A1 (en) 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
FR2817875B1 (en) 2000-12-07 2005-03-18 Technopharm PROCESS FOR THE PREPARATION OF A HUMAN MONOCLONAL ANTIBODY, FRAGMENTS THEREOF OR ANTIBODIES COMPRISING SUCH FRAGMENTS, THE ANTIBODIES THUS OBTAINED AND THEIR USE
ES2727425T3 (en) 2000-12-12 2019-10-16 Medimmune Llc Molecules with prolonged half-lives, compositions and uses thereof
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
JP2007531707A (en) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG
BRPI0417107A (en) 2003-12-19 2007-02-06 Genentech Inc antibody fragment, antibody fragment preparation methods, isolated nucleic acid, compositions, host cell, and antibody fragment manufacture and generation methods
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
PT1974020E (en) 2005-12-16 2011-08-26 Ribovax Biotechnologies Sa Methods for obtaining immortalized antibody secreting cells
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
BRPI0817079A2 (en) 2007-09-07 2016-10-11 Symphogen As processes for recombinant manufacture of anti-rsv antibodies
BRPI0817257A2 (en) 2007-09-24 2015-06-16 Univ Vanderbilt Monoclonal antibodies to respiratory syncytial virus and their uses
IN2012DN01328A (en) 2009-08-13 2015-06-05 Crucell Holland Bv
EP2591000B1 (en) * 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use

Also Published As

Publication number Publication date
AU2010282312A1 (en) 2012-02-23
NZ597996A (en) 2014-02-28
CA2770737A1 (en) 2011-02-17
BR112012003064B8 (en) 2021-05-25
CN102656189A (en) 2012-09-05
US20140044719A1 (en) 2014-02-13
MX2012001882A (en) 2012-04-11
EA201200277A1 (en) 2012-09-28
EP2464664A1 (en) 2012-06-20
ZA201201007B (en) 2019-08-28
SG178335A1 (en) 2012-03-29
DK2464664T3 (en) 2016-01-18
BR112012003064A2 (en) 2017-11-14
IL217977A (en) 2016-06-30
US20110076268A1 (en) 2011-03-31
BR112012003064B1 (en) 2021-03-16
JP5762408B2 (en) 2015-08-12
US8568719B2 (en) 2013-10-29
EA023179B1 (en) 2016-05-31
CN102656189B (en) 2014-10-08
PL2464664T3 (en) 2016-02-29
ES2553440T3 (en) 2015-12-09
US9365638B2 (en) 2016-06-14
HK1172350A1 (en) 2013-04-19
CA2770737C (en) 2020-05-12
WO2011020079A1 (en) 2011-02-17
KR20120050480A (en) 2012-05-18
EP2464664B1 (en) 2015-09-23
KR101778317B1 (en) 2017-09-13
IL217977A0 (en) 2012-03-29
JP2013501527A (en) 2013-01-17

Similar Documents

Publication Publication Date Title
IN2012DN01328A (en)
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
EA201201116A1 (en) MONOCLONAL HUMAN ANTIBODIES OBTAINED FROM HUMAN B-CELLS AND HAVING NEUTRALIZING ACTIVITY AGAINST THE VIRUS AIRFLOWER
MX2010004482A (en) Anti-rsv g protein antibodies.
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
MX2012000035A (en) Recombinant rsv antigens.
MX337932B (en) Modified rsv f proteins and methods of their use.
WO2010056898A3 (en) Rapid expression cloning of human monoclonal antibodies from memory b cells
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
EA201300131A1 (en) COMBINED PHARMACEUTICAL COMPOSITION AND METHODS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES OR CONDITIONS
EA201101643A1 (en) OPTIONS FOR THE USE OF IL-1β ANTIBODIES AND THEIR CONNECTING FRAGMENTS IN THE CARDIOVASCULAR SYSTEM
WO2013095091A3 (en) Rsv g protein specific antibodies
MX2009005026A (en) Anti-tsg101 antibodies and their uses for treatment of viral infections.
WO2010117455A3 (en) Human monoclonal antibodies protective against bubonic plaque
WO2012054739A3 (en) Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
UA108207C2 (en) HIGH-AFIN HUMAN ANTIBODY TO HUMAN ANGIOPOETIN-2
HK1180703A1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
TH156774A (en) Human monoclonal antibodies With specificity for denguexirite 1 E virus proteins and their use (HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF).
WO2011109104A3 (en) Molecular clone of hiv-1